Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2006-12-5
pubmed:abstractText
Insulin-like growth factor binding protein-3 (IGFBP-3) is postulated to be a mediator of growth suppression signals. Here, we examined the methylation status of IGFBP-3 to correlate to clinicopathological factors in human cancers. The methylation status of IGFBP-3 was determined by bisulfite DNA sequencing and was correlated with expression semi-quantified by real-time RT-PCR to develop a methylation-specific PCR (MSP) assay for IGFBP-3. Using the MSP assay, we examined the methylation status of IGFBP-3 in gastric cancer (GC), colorectal cancer (CRC), breast cancer (BC) and malignant mesothelioma (MM). IGFBP-3 methylation was detected in 6 of 13 (46%) and 16 of 24 (67%) GC cell lines and tumors, respectively; 4 of 8 (50%) and 15 of 26 (58%) CRC cell lines and tumors, respectively; 3 of 11 (27%) and 7 of 39 (18%) BC cell lines and tumors, respectively and 1 of 5 (20%) and 18 of 56 (32%) MM cell lines and tumors, respectively. Interestingly, the methylation status of MM specimens from Japanese patients (75%, 12 out of 16 patients) was significantly higher than those from the USA (15%, 6 out of 40 patients) (p < 0.0001), suggesting the presence of ethnic differences in the IGFBP-3 methylation status. We also found that IGFBP-3 methylation was preferentially present in GCs arising in the lower-third of the stomach (p = 0.079). In summary, our results showed that IGFBP-3 methylation played an important role in the silencing of its expression, suggesting that IGFBP-3 may act as a tumor suppressor gene in several human cancers examined.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0020-7136
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
120
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
566-73
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:17096329-5' Flanking Region, pubmed-meshheading:17096329-Cell Line, Tumor, pubmed-meshheading:17096329-Colorectal Neoplasms, pubmed-meshheading:17096329-CpG Islands, pubmed-meshheading:17096329-DNA, Neoplasm, pubmed-meshheading:17096329-DNA Methylation, pubmed-meshheading:17096329-DNA Primers, pubmed-meshheading:17096329-Gene Expression Regulation, Neoplastic, pubmed-meshheading:17096329-HT29 Cells, pubmed-meshheading:17096329-Humans, pubmed-meshheading:17096329-Insulin-Like Growth Factor Binding Protein 3, pubmed-meshheading:17096329-Neoplasms, pubmed-meshheading:17096329-Promoter Regions, Genetic, pubmed-meshheading:17096329-RNA, Messenger, pubmed-meshheading:17096329-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:17096329-Sequence Analysis, DNA, pubmed-meshheading:17096329-Stomach Neoplasms
pubmed:year
2007
pubmed:articleTitle
Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers.
pubmed:affiliation
Department of Cancer and Thoracic Surgery, Shikata Laboratory, Advanced Science Research Center, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't